Evidence for overestimation of the prevalence of malignancy in indeterminate thyroid nodules classified as Bethesda category III

被引:48
作者
Iskandar, Mazen E. [1 ]
Bonomo, Giovanni [1 ]
Avadhani, Vaidehi [2 ]
Persky, Mark [3 ]
Lucido, David [4 ,5 ]
Wang, Beverly [2 ]
Marti, Jennifer L. [1 ]
机构
[1] Icahn Sch Med Mt Sinai, Div Endocrine Surg, Dept Surg, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA
[3] Icahn Sch Med Mt Sinai, Dept Otolaryngol, New York, NY 10029 USA
[4] Icahn Sch Med Mt Sinai, Dept Biostat, New York, NY 10029 USA
[5] Mt Sinai Beth Israel, Mt Sinai Hlth Syst, New York, NY USA
关键词
FINE-NEEDLE-ASPIRATION; UNDETERMINED SIGNIFICANCE; FOLLICULAR LESION; PREDICTIVE-VALUE; FOLLOW-UP; SYSTEM; CYTOPATHOLOGY; MANAGEMENT; ATYPIA; IMPACT;
D O I
10.1016/j.surg.2014.10.004
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Several recent analyses of indeterminate thyroid nodules classified as Bethesda III (follicular lesion of undetermined significance) have reported considerably greater rates of malignancy than those initially reported by the Bethesda System for Reporting Cytopathology (BSRTC). These values, however, may be overestimates owing to several sources of bias, such as referral, selection, and publication biases. Our aim was to analyze the prevalence of malignancy in Bethesda III and IV thyroid nodules in a comprehensive health system less prone to institutional referral bias, excluding incidental carcinomas, and we examine the literature for publication bias. Methods. We performed a retrospective analysis with pathologic re-review of 119 patients with Bethesda III/IV cytology undergoing surgery in a comprehensive health system by examining patient and nodule characteristics. A review of the literature was performed and analyzed for publication bias. Results. The malignancy rate in resected thyroid nodules was 13% (6/48) for Bethesda III and 28% (20/71) for Bethesda IV. There were 9 of 119 patients (8%) with incidental microcarcinomas. Age <30 years was associated with an increased risk of malignancy (odds ratio, 25.8; P = .005). Sex, nodule size, and ultrasonographic features were not associated with risk of malignancy. Analysis of the literature was indicative of publication bias for Bethesda III cohorts, with reported rates positively skewed (P = .039). Conclusion. In a comprehensive health system, the rate of malignancy in Bethesda III nodules was similar to the range reported by the BSRTC. Recent reports of greater rates of malignancy may be attributable to institutional referral patterns, operative selection, inclusion of incidental microcarcinomas, and publication bias.
引用
收藏
页码:510 / 517
页数:8
相关论文
共 50 条
  • [41] Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?
    Turkdogan, Sena
    Pusztaszeri, Marc
    Forest, Veronique-Isabelle
    Hier, Michael P.
    Payne, Richard J.
    CANCERS, 2020, 12 (09) : 1 - 8
  • [42] False-negative Results with the Bethesda System of Reporting Thyroid Cytopathology: Predictors of Malignancy in Thyroid Nodules Classified as Benign by Cytopathologic Evaluation
    Richmond, Bryan K.
    Judhan, Rudy
    Chong, Benny
    Ubert, Adam
    Aburahma, Zachary
    Mangano, William
    Thompson, Stephanie
    AMERICAN SURGEON, 2014, 80 (08) : 811 - 816
  • [43] Improving Diagnostic Performance for Thyroid Nodules Classified as Bethesda Category III or IV: How and by Whom Ultrasonography Should be Performed
    Scerrino, Gregorio
    Cocorullo, Gianfranco
    Mazzola, Sergio
    Melfa, Giuseppina
    Orlando, Giuseppina
    Laise, Iole
    Corigliano, Alessandro
    Lo Brutto, Daniela
    Cipolla, Calogero
    Graceffa, Giuseppa
    JOURNAL OF SURGICAL RESEARCH, 2021, 262 : 203 - 211
  • [44] Diagnostic performance of molecular testing in indeterminate (Bethesda III and IV) thyroid nodules with Hürthle cell cytology
    Raghunathan, Rajam
    Longstaff, Xochitl R.
    Hughes, Elena G.
    Li, Shanpeng J.
    Sant, Vivek R.
    Tseng, Chi-Hong
    Rao, Jianyu
    Wu, James X.
    Yeh, Michael W.
    Livhits, Masha J.
    SURGERY, 2024, 175 (01) : 221 - 227
  • [45] AI diagnosis of Bethesda category IV thyroid nodules
    Yao, Jincao
    Zhang, Yanming
    Shen, Jiafei
    Lei, Zhikai
    Xiong, Jing
    Feng, Bojian
    Li, Xiaoxian
    Li, Wei
    Ou, Di
    Lu, Yidan
    Feng, Na
    Yan, Meiying
    Chen, Jinjie
    Chen, Liyu
    Yang, Chen
    Wang, Lipin
    Wang, Kai
    Zhou, Jianhua
    Liang, Ping
    Xu, Dong
    ISCIENCE, 2023, 26 (11)
  • [46] Histologic Outcome of Indeterminate Thyroid Nodules Classified at Low or High Risk
    Trimboli, Pierpaolo
    Fulciniti, Franco
    Merlo, Elisabetta
    Barizzi, Jessica
    Mazzucchelli, Luca
    Giovanella, Luca
    ENDOCRINE PATHOLOGY, 2018, 29 (01) : 75 - 79
  • [47] Does Bethesda Category Predict Aggressive Features in Malignant Thyroid Nodules?
    Kleiman, David A.
    Beninato, Toni
    Soni, Ashwin
    Shou, Yiyan
    Zarnegar, Rasa
    Fahey, Thomas J., III
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (11) : 3484 - 3490
  • [48] Serum cholesterol levels are inversely associated with the risk of malignancy in subjects with Bethesda category IV thyroid nodules
    Montejo-Marcos, Beatriz
    Lopez-Plasencia, Yaiza
    Marrero-Arencibia, Dunia
    Rodriguez-Perez, Carlos A.
    Boronat, Mauro
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2024, 71 (06): : 246 - 252
  • [49] Risk of malignancy in thyroid nodules classified as TIR-3A: What therapy?
    Medas, Fabio
    Erdas, Enrico
    Gordini, Luca
    Conzo, Giovanni
    Gambardella, Claudio
    Canu, Gian Luigi
    Pisano, Giuseppe
    Nicolosi, Angelo
    Calo, Pietro Giorgio
    INTERNATIONAL JOURNAL OF SURGERY, 2017, 41 : S60 - S64
  • [50] Malignancy Rate of Bethesda Class III Thyroid Nodules Based on the Presence of Chronic Lymphocytic Thyroiditis in Surgical Patients
    Cho, Yoon Young
    Chung, Yun Jae
    Kim, Hee Sung
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12